A neuroscientist, biochemist, and inventor who spent three decades asking a different question: not how to treat disease, but what quietly causes it in the first place.
For most of modern medicine, the approach to disease has been to wait for symptoms, then treat them. Dr. Dayan Goodenowe built his career on the opposite idea — that disease is predictable, that it leaves a biochemical signature long before symptoms appear, and that if you can read that signature early enough, you can change the outcome.
He earned his PhD in medical sciences, with a focus on psychiatry, from the University of Alberta in 1994, and began researching the biochemical mechanisms of disease in 1990. In the thirty-plus years since, he has worked as a neuroscientist, synthetic organic chemist, and inventor — designing diagnostic technologies, manufacturing novel biochemical compounds, and mapping the chemistry that separates a healthy body from a diseased one.
In 1999, Dr. Goodenowe invented and patented a revolutionary ion cyclotron resonance mass spectrometry technology — a platform that, for the first time, made it possible to comprehensively monitor human biochemistry at scale. This became the foundation of a field he helped pioneer: non-targeted metabolomics, the study of thousands of the body’s molecules at once.
Using that platform, he analyzed blood samples from tens of thousands of people — of all ages, races, and nationalities — comparing the biochemistry of healthy individuals against those living with disease. Buried in that data, he found a pattern no one was looking for.
The most consequential pattern Dr. Goodenowe identified was a deficiency in a little-known class of lipids called plasmalogens — molecules essential to the structure of every cell membrane, found in especially high concentrations in the brain and heart. Remarkably, he had never encountered them in his formal training; they simply emerged from the data.
His research linked low plasmalogen levels to Alzheimer’s disease — findings first published in the Journal of Lipid Research in 2007 and since examined by research groups in Japan, Europe, and North America. Because there is no viable dietary source that restores plasmalogens, he went a step further: he designed and patented the first targeted plasmalogen precursors capable of rebuilding these molecules in the body’s cells.
Over his career, his metabolomic research has explored biochemical signatures associated with a wide range of conditions:
“I believe that disease is predictable, and that the leading cause of death is ignorance — not of symptoms, but of the biochemical truth hiding underneath.”
Published in 2021, Dr. Goodenowe’s book chronicles the scientific journey behind the plasmalogen discovery — written for a general audience, translating decades of lipid research into plain language.
Dr. Goodenowe’s current focus reaches past treating illness. His aim is to build what he calls strategic biochemical reserve capacity — strengthening the body’s underlying chemistry so it can maintain function and resilience across a longer, healthier lifespan. It is the same principle that runs through everything Nexus Health Community shares: go to the cause, and the whole system responds.